journal article·2018-02-17Open access

RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies

Venkata Talluri Siddhartha, Sai Kiran S. S. Pindiprolu, Pavan Kumar Chintamaneni, Shashank Tummala, S. Nandha Kumar

Abstract

In the present study, we have demonstrated receptor for advanced glycation endproducts (RAGE) as a target for delivery of drugs specifically to triple negative breast cancer cells. We have prepared solid lipid nanoparticle formulation of cytotoxic agent di-allyl-disulfide (DADS) to overcome its bioavailability issues. Then, we have surface modified DADS-loaded solid lipid nanoparticles (DADS-SLN) with RAGE antibody to achieve site-specific delivery of DADS to TNBC cells. We found a significant cellular internalization of RAGE surface modified DADS-SLN (DADS-RAGE-SLN) when compared to DADS-SLN. The cytotoxic effect of DADS was also significantly improved with DADS-RAGE-SLN by downregulating anti-apoptotic proteins and upregulating pro-apoptotic proteins as observed by western blot analysis. RAGE-targeted delivery of cytotoxic agents can be, therefore, a promising approach for improving antitumour activity and reducing off-target effects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Glycation End Products research · Sesame and Sesamin Research · Phytochemicals and Antioxidant Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam (Jagadguru Sri Shivarathreeshwara University), Tamil Nadu, India;

Department of Pharmacology, JSS College of Pharmacy, Udhagamandalam (Jagadguru Sri Shivarathreeshwara University), Tamil Nadu, India;

Department of Pharmaceutics, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India

References (34)

Show source-provided references
1. 10.1038/3502109310.1038/35021093 ↗
2. 10.1200/JCO.2005.03.384510.1200/JCO.2005.03.3845 ↗
3. 10.3390/nu311096210.3390/nu3110962 ↗
4. 10.1038/modpathol.2010.20010.1038/modpathol.2010.200 ↗
5. 10.1016/S0959-8049(09)70012-710.1016/S0959-8049(09)70012-7 ↗
6. 10.1080/0735790070178423810.1080/07357900701784238 ↗
7. 10.3390/ijms1404795910.3390/ijms14047959 ↗
8. 10.1016/j.mehy.2007.12.01810.1016/j.mehy.2007.12.018 ↗
9. 10.1002/path.428010.1002/path.4280 ↗
10. 10.1016/S0021-9258(18)42138-210.1016/S0021-9258(18)42138-2 ↗
11. 10.1016/S0006-291X(03)01190-210.1016/S0006-291X(03)01190-2 ↗
12. 10.1016/j.bbamcr.2008.11.01610.1016/j.bbamcr.2008.11.016 ↗
13. 10.1038/ncpendmet078610.1038/ncpendmet0786 ↗
14. 10.1007/s11010-013-1680-010.1007/s11010-013-1680-0 ↗
15. 10.1158/0008-5472.CAN-14-216110.1158/0008-5472.CAN-14-2161 ↗
16. 10.2337/diabetes.50.6.149510.2337/diabetes.50.6.1495 ↗
17. 10.1016/j.bbagen.2013.11.01410.1016/j.bbagen.2013.11.014 ↗
18. 10.3109/21691401.2016.117304610.3109/21691401.2016.1173046 ↗
19. 10.1080/10717544.2016.119960610.1080/10717544.2016.1199606 ↗
20. 10.1371/journal.pone.003292010.1371/journal.pone.0032920 ↗
21. 10.1016/j.ijpharm.2008.06.00210.1016/j.ijpharm.2008.06.002 ↗
22. 10.2174/156720181166614041411525910.2174/1567201811666140414115259 ↗
23. Talluri S · 2016 · 57
24. 10.1016/j.colsurfb.2005.08.00510.1016/j.colsurfb.2005.08.005 ↗
25. Zhang L · Int J Nanomedicine · 2015 · 10 · 2101
26. 10.1007/s11095-014-1504-210.1007/s11095-014-1504-2 ↗
27. 10.1038/nprot.2006.17910.1038/nprot.2006.179 ↗
28. 10.3109/10717544.2014.88244610.3109/10717544.2014.882446 ↗
29. Vaupel P · Cancer Res · 1989 · 49 · 6449
30. 10.1096/fj.02-0088com10.1096/fj.02-0088com ↗
31. Gabizon AA. · Cancer Res · 1992 · 52 · 891
32. 10.1016/j.toxlet.2012.10.00810.1016/j.toxlet.2012.10.008 ↗
33. 10.1111/j.1742-4658.2009.07329.x10.1111/j.1742-4658.2009.07329.x ↗
34. 10.4174/jkss.2011.81.2.8510.4174/jkss.2011.81.2.85 ↗